Efficacy and Safety of Tofacitinib in Lichen Planopilaris: A Retrospective Series of 74 Patients
Tofacitinib represents a promising treatment for LPP, providing significant improvement in disease activity for most patients. Further research is needed to refine treatment protocols, understand predictors of response, and address gender-specific adverse effects.
Authors
- Sahar Dadkhahfar (ORCID: https://orcid.org/0000-0003-4058-2562)
- Hamideh Moravvej (ORCID: https://orcid.org/0000-0002-9425-7282)
- Mehdi Goodarzi
- Zahra Razzaghi (ORCID: https://orcid.org/0009-0009-3321-8982)
- Faranak Yahyaei
Institutions
- Shahid Beheshti University of Medical Sciences (IR)
Publication Details
- Journal
- Archives of Iranian Medicine
- Published
- 2024-12-30
- DOI
- https://doi.org/10.34172/aim.33237
- Citations
- 1
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.42